Langerhans’ cell histiocytosis- Introduction, Lab Diagnosis, Treatment, Prevention, and Keynotes

Introduction

• LCH is a rare clonal proliferative disorder of Langerhans cells, a type of dendritic cell involved in antigen presentation.
• It can behave like a neoplastic disorder or immune dysregulation and may affect any organ, particularly the bone, skin, lymph nodes, lungs, and pituitary gland.
• The disease spectrum includes:
  • Eosinophilic granuloma (localized form)
  • Hand-Schüller-Christian disease (chronic disseminated form)
  • Letterer-Siwe disease (acute disseminated form)

Laboratory Diagnosis

1. Histopathology:

• Biopsy of affected tissue shows Langerhans cells with:
  • Grooved, folded, or “coffee-bean” nuclei
  • Background of eosinophils, macrophages, and multinucleated giant cells

2. Immunohistochemistry (IHC):

• Positive for:
  • CD1a
  • Langerin (CD207) – specific marker
  • S-100 protein

3. Electron Microscopy (optional):

• Shows Birbeck granules (rod-shaped organelles with a terminal bulb, resembling “tennis rackets”)

4. Complete Blood Count (CBC):

• May show anemia, thrombocytopenia, or leukopenia in disseminated disease

5. Radiology:

• X-rays/CT/MRI reveal lytic bone lesions, skull defects, or lung nodules.

6. BRAF V600E Mutation:

• Found in about 50-60% of cases (important for prognosis and targeted therapy)

Treatment

Depends on severity and extent:

Single-System Disease:

• Surgical curettage of bone lesions
• Topical steroids for skin involvement

Multisystem Disease:

• Systemic chemotherapy:
  • Vinblastine + Prednisone (standard)
  • Methotrexate, Cytarabine, or Cladribine in refractory cases
• Targeted therapy:
  • BRAF inhibitors (e.g., Vemurafenib) in BRAF-mutant cases

Supportive Care:

• Pain control, endocrine replacement (e.g., diabetes insipidus), and nutritional support

Prevention

• No established primary prevention
• Early detection and prompt treatment prevent complications
• Avoidance of environmental pollutants (e.g., cigarette smoke) may benefit pulmonary LCH

Keynotes

• LCH is not purely malignant, but has features of both inflammation and neoplasia.
• Affects children more commonly, but adult cases occur (especially pulmonary LCH in smokers).
• Birbeck granules and CD1a/Langerin positivity are diagnostic hallmarks.
• May present with bone pain, skin rash, lymphadenopathy, or diabetes insipidus.
• Multidisciplinary management is often required.
• Long-term follow-up is necessary due to the risk of recurrence and endocrine dysfunction.

Further Readings

• https://www.cincinnatichildrens.org/health/l/langerhan-s-cell-histiocytosis-lch
• https://my.clevelandclinic.org/health/diseases/17156-langerhans-cell-histiocytosis
• https://www.dana-farber.org/cancer-care/types/childhood-langerhans-cell-histiocytosis
• https://histio.org/langerhans-cell-histiocyto-sis-in-adults/
• https://www.schn.health.nsw.gov.au/langerhans-cell-histiocytosis-lch-factsheet
• https://www.webmd.com/cancer/cancer-langerhans-cell-histiocytosis
• https://www.rarecancers.org.au/knowledgebase/cancer-types/langerhans-cell-histiocytosis-lch/
• https://www.cancer.columbia.edu/cancer-types-care/types/rare-blood-disorders/conditions/langerhans-cell-histiocytosis-lch